Nanobiotix (NASDAQ:NBTX) Sees Unusually-High Trading Volume – Should You Buy?

Shares of Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX) saw unusually-strong trading volume on Monday . Approximately 49,322 shares changed hands during trading, an increase of 173% from the previous session’s volume of 18,042 shares.The stock last traded at $16.82 and had previously closed at $16.24.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on NBTX shares. HC Wainwright reiterated a “buy” rating on shares of Nanobiotix in a research note on Friday, September 19th. Leerink Partners set a $14.00 price objective on Nanobiotix in a research note on Thursday, September 18th. Two analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $11.00.

Nanobiotix Stock Up 12.9%

The business has a 50 day moving average of $8.94 and a two-hundred day moving average of $5.74.

Institutional Investors Weigh In On Nanobiotix

An institutional investor recently bought a new position in Nanobiotix stock. Jane Street Group LLC acquired a new stake in Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 23,283 shares of the company’s stock, valued at approximately $73,000. 38.81% of the stock is owned by institutional investors.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.